Francois Bertucci
Overview
Explore the profile of Francois Bertucci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
416
Citations
10826
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Blay J, Penel N, Toulmonde M, Valentin T, Chaigneau L, Rios M, et al.
Eur J Cancer
. 2024 Jul;
208:114228.
PMID: 39018632
Rationale: We report a phase II trial (OSAD93) testing CDDP with ifosfamide (IFO), without doxorubicin in neoadjuvant phase, in adult osteosarcoma with a 25 years follow-up. Patients And Methods: This...
12.
de Nonneville A, Kalbacher E, Cannone F, Guille A, Adelaide J, Finetti P, et al.
Mol Oncol
. 2024 Jun;
18(10):2586-2600.
PMID: 38923749
Endometrioid ovarian cancers (EOvC) are usually managed as serous tumors. In this study, we conducted a comprehensive molecular investigation to uncover the distinct biological characteristics of EOvC. This retrospective multicenter...
13.
Collineau B, Goncalves A, Bertucci F, de Nonneville A
Bull Cancer
. 2024 May;
111(7-8):765-781.
PMID: 38772845
Therapeutic options for breast cancer have recently been enriched by new antibody-drug conjugates (ADC), which are now being utilized across all known molecular subtypes. ADCs represent a groundbreaking class of...
14.
Bertucci F, Lerebours F, Ceccarelli M, Guille A, Syed N, Finetti P, et al.
J Transl Med
. 2024 Apr;
22(1):374.
PMID: 38637846
Background: Inflammatory breast cancer (IBC) is the most pro-metastatic form of BC. Better understanding of its enigmatic pathophysiology is crucial. We report here the largest whole-exome sequencing (WES) study of...
15.
Gantzer J, Toulmonde M, Severac F, Chamseddine A, Charon-Barra C, Vinson C, et al.
Cancer
. 2024 Mar;
130(13):2304-2314.
PMID: 38470379
Background: Perivascular epithelioid cell neoplasms (PEComas) encompass a heterogeneous family of mesenchymal tumors. Previously described clinicopathologic features aimed at distinguishing benign from malignant variants but lacked prognostic value. Methods: This...
16.
Van Berckelaer C, Van Laere S, Lee S, Morse M, Geradts J, Dirix L, et al.
Transl Oncol
. 2024 Feb;
43:101907.
PMID: 38412664
Objective: To assess the expression pattern of X-linked inhibitor of apoptosis protein (XIAP), a cellular stress sensor, and delineate the associated changes in the tumor immune microenvironment (TiME) for prognostic...
17.
Jiang Y, Ma D, Jin X, Xiao Y, Yu Y, Shi J, et al.
Nat Cancer
. 2024 Feb;
5(4):673-690.
PMID: 38347143
Molecular profiling guides precision treatment of breast cancer; however, Asian patients are underrepresented in publicly available large-scale studies. We established a comprehensive multiomics cohort of 773 Chinese patients with breast...
18.
Xie X, Chauhan G, Edupuganti R, Kogawa T, Park J, Tacam M, et al.
Cancer Res Commun
. 2024 Jan;
4(1):236.
PMID: 38282551
No abstract available.
19.
Suo J, Zhu K, Zhuang C, Zhong X, Bravaccini S, Maltoni R, et al.
Ann Transl Med
. 2024 Jan;
11(12):409.
PMID: 38213803
Background: Tucidinostat, which is a subtype-selective histone deacetylase inhibitor, has been approved in China for the treatment of hormone receptor-positive (HR) human epidermal growth factor receptor 2-negative (HER2) advanced breast...
20.
Hussain Z, Bertran T, Finetti P, Lohmann E, Mamessier E, Bidaut G, et al.
Cell Commun Signal
. 2024 Jan;
22(1):1.
PMID: 38167013
Background: Pancreatic ductal adenocarcinoma (PDAC) remains a clinically challenging cancer, mainly due to limited therapeutic options and the presence of a highly prominent tumor microenvironment (TME), facilitating tumor progression. The...